(Q40906577)

24 September 2017

1 reference

title

An update on new immunosuppressive drugs undergoing preclinical and clinical trials: potential applications in organ transplantation (English)

1 reference

24 September 2017

main subject

organ transplantation

1 reference

First MR

1

1 reference

24 September 2017

publication date

1 February 1997

1 reference

American Journal of Kidney Diseases

24 September 2017

published in

1 reference

24 September 2017

volume

29

1 reference

24 September 2017

issue

2

1 reference

24 September 2017

page(s)

303-317

1 reference

Renal transplantation for the nephrologist: new immunosuppressive drugs

24 September 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0272-6386%2897%2990046-9

7 January 2021

Monoclonal antibodies in organ transplantation

1 reference

https://api.crossref.org/works/10.1016%2FS0272-6386%2897%2990046-9

7 January 2021

Relevant targets for therapy with monoclonal antibodies in allograft transplantation

1 reference

https://api.crossref.org/works/10.1016%2FS0272-6386%2897%2990046-9

7 January 2021

Monoclonal antibodies in organ transplantation: an overview

1 reference

https://api.crossref.org/works/10.1016%2FS0272-6386%2897%2990046-9

7 January 2021

Prevention and management of the adverse effects associated with immunosuppressive therapy

1 reference

https://api.crossref.org/works/10.1016%2FS0272-6386%2897%2990046-9

7 January 2021

Chemistry and Biology of the Immunophilins and Their Immunosuppressive Ligands

1 reference

https://api.crossref.org/works/10.1016%2FS0272-6386%2897%2990046-9

7 January 2021

https://api.crossref.org/works/10.1016%2FS0272-6386%2897%2990046-9

1 reference

7 January 2021

Cyclosporine concentration determinations for monitoring and pharmacokinetic studies

1 reference

https://api.crossref.org/works/10.1016%2FS0272-6386%2897%2990046-9

7 January 2021

The adverse impact of high cyclosporine. Clearance rates on the incidences of acute rejection and graft loss

1 reference

https://api.crossref.org/works/10.1016%2FS0272-6386%2897%2990046-9

7 January 2021

Cyclosporine nephrotoxicity

1 reference

https://api.crossref.org/works/10.1016%2FS0272-6386%2897%2990046-9

7 January 2021

Risk factors for cyclosporine-induced nephropathy in patients with autoimmune diseases. International Kidney Biopsy Registry of Cyclosporine in Autoimmune Diseases

1 reference

https://api.crossref.org/works/10.1016%2FS0272-6386%2897%2990046-9

7 January 2021

Absorption characteristics of a microemulsion formulation of cyclosporine in de novo pediatric liver transplant recipients

1 reference

https://api.crossref.org/works/10.1016%2FS0272-6386%2897%2990046-9

7 January 2021

Inhibition of cytokine production by cyclosporine A and G

1 reference

https://api.crossref.org/works/10.1016%2FS0272-6386%2897%2990046-9

7 January 2021

Experimental nephrotoxicity, hepatotoxicity and pharmacokinetics of cyclosporin G versus cyclosporin A

1 reference

https://api.crossref.org/works/10.1016%2FS0272-6386%2897%2990046-9

7 January 2021

The efficacy and tolerability of cyclosporine G in human kidney transplant recipients

1 reference

https://api.crossref.org/works/10.1016%2FS0272-6386%2897%2990046-9

7 January 2021

A randomized, prospective, double-blinded trial of cyclosporine vs. OG37-325 in cadaveric renal transplantation--a preliminary report

1 reference

https://api.crossref.org/works/10.1016%2FS0272-6386%2897%2990046-9

7 January 2021

Evidence that the immunosuppressive effects of FK506 and cyclosporine are identical

1 reference

https://api.crossref.org/works/10.1016%2FS0272-6386%2897%2990046-9

7 January 2021

Tacrolimus. A review of its pharmacology, and therapeutic potential in hepatic and renal transplantation

1 reference

https://api.crossref.org/works/10.1016%2FS0272-6386%2897%2990046-9

7 January 2021

Probing Immunosuppressant Action with a Nonnatural Immunophilin Ligand

1 reference

https://api.crossref.org/works/10.1016%2FS0272-6386%2897%2990046-9

7 January 2021

Atomic structure of FKBP-FK506, an immunophilin-immunosuppressant complex

1 reference

https://api.crossref.org/works/10.1016%2FS0272-6386%2897%2990046-9

7 January 2021

Effects of a novel immunosuppressive agent, FK506, on human B cell activation

1 reference

https://api.crossref.org/works/10.1016%2FS0272-6386%2897%2990046-9

7 January 2021

Combined immunosuppressive therapy with low dose FK506 and antimetabolites in rat allogeneic heart transplantation

1 reference

https://api.crossref.org/works/10.1016%2FS0272-6386%2897%2990046-9

7 January 2021

The relative effects of FK506 and cyclosporine on short- and long-term kidney graft survival

1 reference

https://api.crossref.org/works/10.1016%2FS0272-6386%2897%2990046-9

7 January 2021

A multicenter trial of FK506 (tacrolimus) therapy in refractory acute renal allograft rejection. A report of the Tacrolimus Kidney Transplantation Rescue Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0272-6386%2897%2990046-9

7 January 2021

A Comparison of Tacrolimus (FK 506) and Cyclosporine for Immunosuppression in Liver Transplantation

1 reference

https://api.crossref.org/works/10.1016%2FS0272-6386%2897%2990046-9

7 January 2021

The impact of immunosuppressive regimens on the cost of liver transplantation--results from the U.S. FK506 multicenter trial.

1 reference

https://api.crossref.org/works/10.1016%2FS0272-6386%2897%2990046-9

7 January 2021

A comparison of renal function in cyclosporine- and FK-506-treated patients after primary orthotopic liver transplantation

1 reference

https://api.crossref.org/works/10.1016%2FS0272-6386%2897%2990046-9

7 January 2021

Effect of the immunosuppressant FK506 on glucose-induced insulin secretion from adult rat islets of Langerhans

1 reference

https://api.crossref.org/works/10.1016%2FS0272-6386%2897%2990046-9

7 January 2021

Hypertrophic cardiomyopathy associated with tacrolimus in paediatric transplant patients

1 reference

https://api.crossref.org/works/10.1016%2FS0272-6386%2897%2990046-9

7 January 2021

Preclinical evaluation of a new potent immunosuppressive agent, rapamycin

1 reference

https://api.crossref.org/works/10.1016%2FS0272-6386%2897%2990046-9

7 January 2021

Rapamycin-FKBP specifically blocks growth-dependent activation of and signaling by the 70 kd S6 protein kinases

1 reference

https://api.crossref.org/works/10.1016%2FS0272-6386%2897%2990046-9

7 January 2021

Production of synergistic but nonidentical mechanisms of immunosuppression by rapamycin and cyclosporine

1 reference

https://api.crossref.org/works/10.1016%2FS0272-6386%2897%2990046-9

7 January 2021

Effects of cyclosporin, FK506, and rapamycin on graft-vessel disease

1 reference

https://api.crossref.org/works/10.1016%2FS0272-6386%2897%2990046-9

7 January 2021

Toxicity of rapamycin--a comparative and combination study with cyclosporine at immunotherapeutic dosage in the rat

1 reference

https://api.crossref.org/works/10.1016%2FS0272-6386%2897%2990046-9

7 January 2021

Rapamycin (sirolimus, rapamune).

1 reference

https://api.crossref.org/works/10.1016%2FS0272-6386%2897%2990046-9

7 January 2021

The side effect profile of sirolimus: a phase I study in quiescent cyclosporine-prednisone-treated renal transplant patients

1 reference

https://api.crossref.org/works/10.1016%2FS0272-6386%2897%2990046-9

7 January 2021

Leflunomide, a novel immunosuppressive agent. The mechanism of inhibition of T cell proliferation

1 reference

https://api.crossref.org/works/10.1016%2FS0272-6386%2897%2990046-9

7 January 2021

Guanine ribonucleotide depletion inhibits T cell activation. Mechanism of action of the immunosuppressive drug mizoribine

1 reference

https://api.crossref.org/works/10.1016%2FS0272-6386%2897%2990046-9

7 January 2021

Mizoribine serum levels associated with enterotoxicity in the dog.

1 reference

https://api.crossref.org/works/10.1016%2FS0272-6386%2897%2990046-9

7 January 2021

Lymphocyte-Selective Cytostatic and Immunosuppressive Effects of Mycophenolic Acid in Vitro: Role of Deoxyguanosine Nucleotide Depletion

1 reference

https://api.crossref.org/works/10.1016%2FS0272-6386%2897%2990046-9

7 January 2021

Experience with mycophenolate mofetil (RS61443) in renal transplantation at a single center

1 reference

https://api.crossref.org/works/10.1016%2FS0272-6386%2897%2990046-9

7 January 2021

A BLINDED, RANDOMIZED CLINICAL TRIAL OF MYCOPHENOLATE MOFETIL FOR THE PREVENTION OF ACUTE REJECTION IN CADAVERIC RENAL TRANSPLANTATION1

1 reference

https://api.crossref.org/works/10.1016%2FS0272-6386%2897%2990046-9

7 January 2021

The effect of a new immunosuppressive drug, brequinar sodium, on heart, liver, and kidney allograft rejection in the rat

1 reference

https://api.crossref.org/works/10.1016%2FS0272-6386%2897%2990046-9

7 January 2021

The synergistic interactions in vitro and in vivo of brequinar sodium with cyclosporine or rapamycin alone and in triple combination

1 reference

https://api.crossref.org/works/10.1016%2FS0272-6386%2897%2990046-9

7 January 2021

15-Deoxyspergualin for induction of graft nonreactivity after cardiac and renal allotransplantation in primates

1 reference

https://api.crossref.org/works/10.1016%2FS0272-6386%2897%2990046-9

7 January 2021

Evidence that deoxyspergualin prevents sensitization and first-set cardiac xenograft rejection in rats by suppression of antibody formation

1 reference

https://api.crossref.org/works/10.1016%2FS0272-6386%2897%2990046-9

7 January 2021

Suppression of liver allograft rejection by administration of 15-deoxyspergualin. Comparison of administration via the hepatic artery, portal vein, or systemic circulation

1 reference

https://api.crossref.org/works/10.1016%2FS0272-6386%2897%2990046-9

7 January 2021

Interaction of the immunosuppressant deoxyspergualin with a member of the Hsp70 family of heat shock proteins

1 reference

https://api.crossref.org/works/10.1016%2FS0272-6386%2897%2990046-9

7 January 2021

Deoxyspergualin for liver graft rejection

1 reference

https://api.crossref.org/works/10.1016%2FS0272-6386%2897%2990046-9

7 January 2021

Deoxyspergualin in allogeneic kidney and xenogeneic islet transplantation: early clinical trials

1 reference

https://api.crossref.org/works/10.1016%2FS0272-6386%2897%2990046-9

7 January 2021

Insulin independence in type I diabetes after transplantation of unpurified islets from single donor with 15-deoxyspergualin

1 reference

https://api.crossref.org/works/10.1016%2FS0272-6386%2897%2990046-9

7 January 2021

Induction of non-specific suppressor cells in normal Lewis rats by a novel azaspirane SK&F 105685.

1 reference

https://api.crossref.org/works/10.1016%2FS0272-6386%2897%2990046-9

7 January 2021

The Yin and Yang of T cell costimulation

1 reference

https://api.crossref.org/works/10.1016%2FS0272-6386%2897%2990046-9

7 January 2021

https://api.crossref.org/works/10.1016%2FS0272-6386%2897%2990046-9

1 reference

7 January 2021

CTLA-4 is a second receptor for the B cell activation antigen B7

1 reference

https://api.crossref.org/works/10.1016%2FS0272-6386%2897%2990046-9

7 January 2021

Mechanisms of T cell recognition of alloantigen. The role of peptides

1 reference

https://api.crossref.org/works/10.1016%2FS0272-6386%2897%2990046-9

7 January 2021

10.1016/S0272-6386(97)90046-9

Identifiers

DOI

1 reference

24 September 2017

1 reference